Research & Clinical Trials
Research & Clinical Trials
Built for the pace
your trial needs.
Fast protocol activation. Deep therapeutic expertise. Multi-modality imaging and in-house radiopharmacy under one roof. For investigator-led and sponsor-led clinical trials, Initio is built to move.
Site activation
Under one roof
Radiopharmacy
Trained research staff
Why sponsors choose Initio
Built to score well on every criterion.
Sponsors evaluate sites on activation speed, enrollment, infrastructure, investigator expertise, and data quality. Initio is built, deliberately, to score well on each.
We move from first contact to site initiation substantially faster than the large academic-center average.
Pioneers of Canadian nuclear medicine, published theranostics researchers, and active clinicians in prostate, NET, and neurodegenerative disease.
PET/CT, SPECT/CT, MRI, CT, mammography, ABUS, DEXA — all in the same facility, no inter-site travel.
Agile compounding and dispensing on our own schedule, supporting novel and investigational tracers.
An established pipeline from the US and abroad — meaningful where enrollment is the bottleneck.
Standardized protocols, independent review capacity, GCP-trained staff, and Canadian and international data-integrity experience.
Fast site activation
Compressing the slowest part of a trial.
Site activation — contract execution to first patient in — is where many trials lose time. Our structure is designed to compress it.
A named research-operations lead takes your trial from inquiry through closeout — not a rotating assignment.
Template-based sponsor contracts with parallel — not serial — legal and finance review.
Active working relationships with the research ethics boards we submit to, including expedited pathways where appropriate.
Imaging, radiopharmacy, records, and workflows already documented and standardized for trial use.
GCP training, site-specific SOPs, and role competencies maintained continuously.
For timeline-critical sponsors, accelerated packages that front-load setup in parallel with regulatory review.
Infrastructure & capabilities
Everything a protocol may require.
PET/CT (FDG, PSMA, DOTATATE, amyloid) and SPECT/CT with bone, cardiac, and specialized protocols.
Wide-bore MRI with standard and investigational sequences; multi-slice CT with contrast.
Mammography and automated breast ultrasound (ABUS).
DEXA for longitudinal bone-density tracking.
Licensed in-house radiopharmacy for approved and investigational compounding and dispensing.
Private infusion suites, radiation-safety-compliant uptake rooms, dedicated administration protocols.
DICOM transfer, EDC compatibility, PIPEDA-grade PHI handling; central- and site-read imaging models.
Therapeutic areas
Where our expertise runs deepest.
Prostate cancer imaging and radioligand therapy, with investigators experienced in international Phase III trials.
Imaging and radioligand therapy supported by our DOTATATE capability and specialized team.
Amyloid PET, SPECT evaluations, and emerging tracer studies; medical director dual-certified in psychiatry and nuclear medicine.
PET- and SPECT-based cardiac imaging, perfusion, and viability assessment.
Image-guided procedural capability for protocols with interventional components.
Active engagement in investigational radiopharmaceutical trials and early-phase compound evaluation.
Principal investigators
Leaders across nuclear medicine and oncology.
Pioneer of Canadian nuclear medicine. Division Head at Lions Gate Hospital since 1983.
Dual-certified Psychiatry & Nuclear Medicine. Co-author of national brain-perfusion SPECT guidelines.
Assistant Professor, University of Toronto. Staff physician at Sunnybrook.
Chief Medical Officer, BC Cancer. Lead PI on international Phase III prostate-cancer trials.
Dual-trained clinical researcher and medical physicist.
Provincial Director of Systemic Therapy Clinical Trials at BC Cancer.
Surgeon-scientist at the Vancouver Prostate Centre.
Partnership models
However your trial is structured.
Recruitment, consent, imaging, therapy administration, data capture — end-to-end delivery.
For trials with primary sites elsewhere, we integrate as the imaging arm.
Compounding and dispensing of novel or specialized radiopharmaceuticals under appropriate frameworks.
Support for research originating from our own clinical team.
Rapid activation as an added site for sponsors seeking more enrollment capacity in Canada.
How we engage
From RFI to first patient.
Within five business days of a protocol summary or RFI: PI assignment, operational plan, enrollment projections, and indicative timeline.
Joint discussion with our research-operations lead and assigned PI; technical review of protocol requirements.
Tailored budget against protocol activities; template-based MCA or sponsor structure, with parallel review.
Standard SQV — facility tour, radiopharmacy review, equipment documentation, staff introductions.
REB submission, SOP finalization, staff training, equipment qualification.
Sponsor-led SIV and transition to active enrollment.
Get in touch
Get in touch.
For protocol inquiries, capability statements, or to schedule a feasibility consultation, reach our research team at research@initiomedical.ca. Response within five business days for capability statements, and within two business days for time-sensitive inquiries.